Celia Rubio-Fernandez

Leon, CL 24007, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

An Immunocompetent Hepatic Organoid Model Reveals Conserved Hepatic Immune Dysregulation During Leishmania donovani Infection.

An Immunocompetent Hepatic Organoid Model Reveals Conserved Hepatic Immune Dysregulation During Leishmania donovani Infection.

Journal: International journal of molecular sciences

Published: July 24, 2026

Antileishmanial and Immunomodulatory Activity of Paclitaxel and Docetaxel Combined with Miltefosine and Paromomycin.

Antileishmanial and Immunomodulatory Activity of Paclitaxel and Docetaxel Combined with Miltefosine and Paromomycin.

Journal: International journal of molecular sciences

Published: February 25, 2026

Leishmanicidal Action of the Peptides 19-4LF, 19-2.5 and 19-2.5LF Topically Administered on Cutaneous Lesions Caused by Leishmania major.

Leishmanicidal Action of the Peptides 19-4LF, 19-2.5 and 19-2.5LF Topically Administered on Cutaneous Lesions Caused by Leishmania major.

Journal: Pharmaceutics

Published: December 25, 2025

Development of a High-Throughput Screening Platform and a Pathogenesis Model for Leishmania Infection Based on Mouse Hepatic Organoids.

Development of a High-Throughput Screening Platform and a Pathogenesis Model for Leishmania Infection Based on Mouse Hepatic Organoids.

Journal: International journal of molecular sciences

Published: December 03, 2025

Discovery of Potential Antileishmanial Compounds Through Phenotypic Screening of an Alkaloid Library.

Discovery of Potential Antileishmanial Compounds Through Phenotypic Screening of an Alkaloid Library.

Journal: Molecules (Basel, Switzerland)

Published: September 25, 2025

The Role of BRCT Domain from LmjPES in Leishmania major Pathogenesis.

The Role of BRCT Domain from LmjPES in Leishmania major Pathogenesis.

Journal: Biomolecules

Published: July 10, 2025

Promising aryl selenoate derivatives as antileishmanial agents and their effects on gene expression.

Promising aryl selenoate derivatives as antileishmanial agents and their effects on gene expression.

Journal: Antimicrobial agents and chemotherapy

Published: March 18, 2024

Neglected Zoonotic Diseases: Advances in the Development of Cell-Penetrating and Antimicrobial Peptides against Leishmaniosis and Chagas Disease.

Neglected Zoonotic Diseases: Advances in the Development of Cell-Penetrating and Antimicrobial Peptides against Leishmaniosis and Chagas Disease.

Journal: Pathogens (Basel, Switzerland)

Published: June 26, 2023

Characterization of Leishmania Parasites Isolated from Naturally Infected Mammals.

Characterization of Leishmania Parasites Isolated from Naturally Infected Mammals.

Journal: Animals : an open access journal from MDPI

Published: May 26, 2023

BRCT Domains: Structure, Functions, and Implications in Disease-New Therapeutic Targets for Innovative Drug Discovery against Infections.

BRCT Domains: Structure, Functions, and Implications in Disease-New Therapeutic Targets for Innovative Drug Discovery against Infections.

Journal: Pharmaceutics

Published: May 18, 2023

Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis.

Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis.

Journal: Pharmaceutics

Published: October 19, 2022

The BRCT Domain from the Homologue of the Oncogene PES1 in Leishmania major (LmjPES) Promotes Malignancy and Drug Resistance in Mammalian Cells.

The BRCT Domain from the Homologue of the Oncogene PES1 in Leishmania major (LmjPES) Promotes Malignancy and Drug Resistance in Mammalian Cells.

Journal: International journal of molecular sciences

Published: September 23, 2022

Showing 1-12 of 25

Last Updated: 09/26/2026